Turning Point Brands, Inc. (TPB) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong financial performance with a 29% revenue increase and a 14% rise in adjusted EBITDA. The company is expanding its sales force and manufacturing capabilities, indicating growth potential. Despite some declines in Zig-Zag segment sales, the focus on Modern Oral products shows strategic prioritization. Positive guidance on nicotine pouch sales and adjusted EBITDA, alongside a $100 million capital raise, suggests confidence in future growth. The Q&A section highlighted strategic investments and market opportunities, with management addressing potential risks effectively. Overall, the sentiment is positive, anticipating a stock price increase.
Key Financial Performance
Revenue Revenue increased 29% to $121 million for the fourth quarter, including $41.3 million in Modern Oral net revenue. The increase was driven primarily by growth in Modern Oral sales.
Adjusted EBITDA Adjusted EBITDA increased 14% to $30 million for the quarter, with a margin of 24.8%. The increase was supported by growth in Modern Oral sales and strategic investments in sales and marketing.
Net White Pouch Sales Net white pouch sales increased by 266% year-over-year, and gross sales increased 337%. The growth was attributed to the expansion of FRE's distribution and ALP's entry into bricks-and-mortar retail.
Stoker's Segment Net Revenue Stoker's segment net revenue increased 70% year-over-year to $81 million, reflecting a 9% increase in legacy brands and a 266% increase in Modern Oral revenue.
Zig-Zag Segment Net Sales Zig-Zag segment net sales were down 13% year-over-year to $40 million for the quarter. The decline was anticipated due to a strategic focus on Modern Oral.
Gross Margin Gross margin was 55.9%, which remained flat compared to the previous year.
SG&A Expenses SG&A expenses were $47.7 million for the quarter, up $3.1 million sequentially. The increase was driven by planned investments in Modern Oral sales and marketing and higher outbound freight charges.
Free Cash Flow Free cash flow for the fourth quarter was $19.2 million.
CapEx CapEx for the quarter was $3.3 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Modern Oral nicotine pouch brands (FRE and ALP): Net sales increased by 266% year-over-year, achieving $41.3 million in revenue for Q4. Gross sales increased 337%. ALP expanded from D2C to bricks-and-mortar distribution ahead of schedule, with significant expansion expected in Q2 2026.
Stoker's Proud: Launched a new flanker brand offering traditional long cut dip, targeting value-seeking consumers while maintaining brand quality.
Expansion of FRE and ALP distribution: FRE expanded distribution to large regional and national convenience store chains. ALP began appearing in bricks-and-mortar stores, moving beyond its initial D2C model.
International market expansion: Plans to expand FRE and ALP into international markets.
Sales force expansion: Ahead of schedule in doubling the size of the sales force to support Modern Oral brands.
Manufacturing capabilities: New Louisville factory production lines expected to be qualified in the coming months to support white pouch brands.
Focus on Modern Oral brands: Reallocating resources to prioritize FRE and ALP while maintaining cash flow from legacy brands. Investments include sales and marketing, online presence, chain accounts, and brand partnerships.
Zig-Zag brand evolution: Advanced rollout of natural leaf flat wraps and expanded brand into lifestyle platforms with new apparel lines and cultural initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Zig-Zag Segment Decline: Net sales for the Zig-Zag segment decreased by 13% year-over-year to $40 million for the quarter, which was in line with expectations. This decline reflects anticipated opportunity costs due to the company's focus on Modern Oral products.
Increased SG&A Expenses: Reported SG&A expenses rose by $3.1 million sequentially, driven by planned investments in Modern Oral sales and marketing as well as increased outbound freight charges. This could pressure margins if revenue growth does not offset these costs.
Modern Oral Investment Risks: The company is making significant investments in Modern Oral nicotine pouch brands, including sales and marketing, manufacturing, and distribution. These front-loaded investments may not yield the expected long-term consumer retention and revenue growth, posing a financial risk.
Supply Chain and Manufacturing Challenges: The company is building out U.S. manufacturing for its white pouch brands and expects to qualify production lines at a new factory. Delays or inefficiencies in this process could disrupt supply and impact revenue.
Competitive Market Pressures: The nicotine pouch market is expected to consolidate to 5-6 widely distributed brands. Achieving and maintaining a double-digit market share in this competitive environment will require sustained investment and strategic execution.
Economic and Pricing Pressures: The launch of Stoker's Proud aims to attract value-seeking consumers while insulating the broader brand from pricing pressures. However, economic uncertainties and pricing competition could impact profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Modern Oral gross revenue guidance: $220 million to $240 million
2026 Modern Oral net revenue guidance: $180 million to $190 million
First quarter 2026 consolidated adjusted EBITDA: Expected to be between $24 million and $27 million
Long-term target for Modern Oral market share: Double-digit market share in the category
Projected size of the nicotine pouch market: Expected to approach or exceed $10 billion in manufacturers' revenue by the end of the decade
Expansion of ALP distribution: Significant expansion into bricks-and-mortar distribution expected during Q2 2026
Manufacturing progress: First production lines at the new Louisville factory expected to be qualified over the next several months
Sales force expansion: Ahead of schedule in doubling the size of the sales force
2026 CapEx budget: $4 million to $5 million, exclusive of Modern Oral projects
Modern Oral PMTAs spending for 2026: Expected to be between $3 million to $5 million
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the sales and marketing opportunities for nicotine pouch growth this year?
A:The company is investing in sales and marketing and preparing for the launch of ALP in brick-and-mortar stores in Q2. Investments are being made upfront to ensure a successful launch.
Q:What is the outlook for domestic production this year, including the mix of domestic versus international production?
A:The company expects to qualify production lines in the next few months. Investments in infrastructure have been made, and domestic production will supplement growth alongside the Indian partner. Margins are expected to improve towards the end of the year, with a focus on optimizing inbound freight.
Q:What is the timing and sustainable rate of investment for Modern Oral products?
A:Investments will be lumpy throughout the year, focusing on high ROI projects. The investment ratio will modulate quarter-to-quarter.
Q:What should we expect for the store count ramp for ALP?
A:The store count growth for ALP is expected to resemble the early days of the FRE launch, focusing on areas with existing distribution and chain wins.
Q:What are the expectations for FRE's brick-and-mortar distribution and white space opportunities in 2026?
A:There is significant store opportunity in both chain and independent environments. The focus is on increasing distribution, share of shelf, and store maturity. Store growth is expected to continue, though it may be lumpy due to chain onboarding.
Q:How is the company approaching innovation in the category, especially with the FDA's fast-track PMTA program?
A:The focus is on winning with existing products, which have strong flavor profiles and satisfaction levels. Long-term innovation may include additional flavor options, but the current portfolio is deemed sufficient to compete.
Q:How do you see growth evolving in the nicotine pouch industry—through existing consumers or new users?
A:Growth is expected from both existing consumers increasing usage and new users entering the category, particularly transitioning from other tobacco products like cigarettes and vapes.
Q:What is the potential impact of state-level tax hikes on nicotine pouches?
A:Tax hikes are expected to grow over time but will impact all manufacturers equally. The company sees no disadvantage and believes it has a winning product to compete in taxed environments.
Q:Can you provide insights into the revenue performance between FRE and ALP this quarter?
A:Both brands performed within expectations. Specific revenue details were not disclosed.
Q:What are the biggest white space opportunities for distribution, and how do you balance entering larger chains versus expanding in existing stores?
A:There is significant white space for ALP and FRE in terms of store-level distribution and portfolio expansion within existing stores. The company is investing in sales force, trade programs, and strategic partnerships to capitalize on these opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue details for FRE and ALP, citing internal reasons. Additionally, they did not provide exact figures for investment ratios or store count growth, using vague language like 'lumpy' and 'modulate quarter-to-quarter.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALP DC
FRE ALP
Modern Oral
Modern sale
Summer
Zig Zag
approach
awareness
brick mortar
category
chain
consumer base
distribution
ethos
investment pouch
leaf
legacy brand
manufacturing
marketing investment
merchandising
nicotine pouch
pouch brand
pouch sale
premium
press release
sale force
sale marketing
schedule
segment sale
shelf
size
space
TPB Transcript
Turning Point Brands, Inc. (TPB) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call shows strong sales growth, particularly in the Modern Oral segment, with gross and net sales up significantly year-over-year and sequentially. Despite some market expansion challenges and execution risks, the overall financial performance is robust. The lack of negative sentiment in the Q&A and no mention of shareholder returns do not detract from the positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term.
Turning Point Brands, Inc. (TPB) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call revealed strong financial performance with a 29% revenue increase and a 14% rise in adjusted EBITDA. The company is expanding its sales force and manufacturing capabilities, indicating growth potential. Despite some declines in Zig-Zag segment sales, the focus on Modern Oral products shows strategic prioritization. Positive guidance on nicotine pouch sales and adjusted EBITDA, alongside a $100 million capital raise, suggests confidence in future growth. The Q&A section highlighted strategic investments and market opportunities, with management addressing potential risks effectively. Overall, the sentiment is positive, anticipating a stock price increase.
Air Canada (AC:CA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call indicates positive sentiment with increased guidance for EBITDA and nicotine pouch sales. The Q&A section confirms a favorable revenue environment and strategic growth plans, such as sales force expansion and market share targets. Although there are some concerns, like headwinds in the Zig-Zag segment, the overall outlook remains optimistic with strong modern oral sales projections and strategic investments. The increased guidance and strategic initiatives suggest a likely positive stock price movement.
Turning Point Brands, Inc. (TPB) Q3 2025 Earnings Call Transcript
Positive11-5
The company's earnings call highlights an increase in EBITDA guidance and nicotine pouch sales, indicating strong financial performance. The Q&A section reveals confidence in capacity expansion and strategic growth in Modern Oral products. Despite some margin pressures and negative free cash flow, the company's positive guidance and strategic investments in growth areas suggest a likely positive stock price reaction.
TPB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
